Company’s 36-month beta value is 0.42.Analysts have differing opinions on the stock, with 4 analysts rating it as a “buy,” 2 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ACRS is 92.25M, and currently, short sellers hold a 5.10% ratio of that floaft. The average trading volume of ACRS on June 26, 2025 was 773.33K shares.
ACRS) stock’s latest price update
The stock price of Aclaris Therapeutics Inc (NASDAQ: ACRS) has jumped by 7.24 compared to previous close of 1.52. Despite this, the company has seen a gain of 16.43% in its stock price over the last five trading days. globenewswire.com reported 2025-06-23 that – Potential Best-In-Class Bispecific Antibody ATI-052 Targets Both Thymic Stromal Lymphopoietin (TSLP) and Interleukin-4 Receptor (IL-4R) – WAYNE, Pa., June 23, 2025 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4R antibody.
ACRS’s Market Performance
Aclaris Therapeutics Inc (ACRS) has experienced a 16.43% rise in stock performance for the past week, with a 29.37% rise in the past month, and a -2.40% drop in the past quarter. The volatility ratio for the week is 5.87%, and the volatility levels for the past 30 days are at 4.62% for ACRS.. The simple moving average for the past 20 days is 9.54% for ACRS’s stock, with a -15.66% simple moving average for the past 200 days.
Analysts’ Opinion of ACRS
Many brokerage firms have already submitted their reports for ACRS stocks, with Wedbush repeating the rating for ACRS by listing it as a “Outperform.” The predicted price for ACRS in the upcoming period, according to Wedbush is $8 based on the research report published on May 28, 2025 of the current year 2025.
H.C. Wainwright gave a rating of “Buy” to ACRS, setting the target price at $20 in the report published on December 23rd of the previous year.
ACRS Trading at 20.67% from the 50-Day Moving Average
After a stumble in the market that brought ACRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -68.47% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ACRS starting from Mehra Anand, who purchase 666,666 shares at the price of $2.25 back on Nov 19 ’24. After this action, Mehra Anand now owns 710,030 shares of Aclaris Therapeutics Inc, valued at $1,499,998 using the latest closing price.
Leonard Braden Michael, the 10% Owner of Aclaris Therapeutics Inc, purchase 206,025 shares at $1.24 during a trade that took place back on Aug 05 ’24, which means that Leonard Braden Michael is holding 14,250,000 shares at $256,357 based on the most recent closing price.
Stock Fundamentals for ACRS
Current profitability levels for the company are sitting at:
- -7.92 for the present operating margin
- 0.21 for the gross margin
The net margin for Aclaris Therapeutics Inc stands at -7.32. The total capital return value is set at -0.8. Equity return is now at value -91.03, with -69.97 for asset returns.
Currently, EBITDA for the company is -51.72 million with net debt to EBITDA at 0.56. When we switch over and look at the enterprise to sales, we see a ratio of 8.22. The receivables turnover for the company is 71.11for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.06.
Conclusion
In a nutshell, Aclaris Therapeutics Inc (ACRS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
